Infant exposure to multiple sclerosis treatments during breastfeeding


  • This study demonstrates that potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA), does not increase the risk of adverse infant events. Thus, women with multiple sclerosis (MS) taking INF-β or GA postpartum may be encouraged to breastfeed due to the positive health outcomes associated with breastfeeding.

Why this matters

  • Breastfeeding mothers with MS are concerned about the breast milk exposure of disease-modifying therapies (DMTs) and the potential health risks to their child.

  • Currently, there is little data available on breastfeeding while taking DMTs.